☆ 4.4 Article

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

DERMATOLOGY AND THERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Dermatology

Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a US commercially insured population

Chang Xu et al.

Summary: This study examined adherence and persistence among psoriasis patients with comorbid psoriatic arthritis who initiated treatment with different biologics. The results showed that patients who initiated treatment with guselkumab and ustekinumab had the highest rates of adherence and persistence.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Add to Collection

Article Rheumatology

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Alexander Egeberg et al.

Summary: This study examined the real-life drug survival of biologics and novel small-molecule therapies for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis. Results showed varying treatment responses to drugs with different mechanisms of action across the diseases, emphasizing the need for individualized treatment approaches.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2022)

Add to Collection

Article Dermatology

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA

Dominic Pilon et al.

Summary: Ustekinumab for the treatment of psoriasis has lower discontinuation risk compared to other biologics, indicating better treatment persistence.

DERMATOLOGY AND THERAPY (2022)

Add to Collection

Article Dermatology

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab

Andrew Blauvelt et al.

Summary: This study compared real-life psoriasis drug treatment patterns between ixekizumab and guselkumab using United States insurance claims data, and found that patients treated with ixekizumab had greater adherence and similar or longer persistence compared to guselkumab.

DERMATOLOGY AND THERAPY (2022)

Add to Collection

Article Dermatology

Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis

Zenas Z. N. Yiu et al.

Summary: The results of this cohort study suggest that guselkumab had the highest drug survival among the included biologics for treating psoriasis in terms of effectiveness, and guselkumab had the highest drug survival for safety compared with other biologics except ustekinumab.

JAMA DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Failure rates and survival times of systemic and biologic therapies in treating psoriasis: a retrospective study

Nishadh Sutaria et al.

Summary: Systemic therapies fail more often due to adverse effects, while biologics fail more often due to loss of efficacy. Biologic therapies have longer survival times than systemic therapies.

JOURNAL OF DERMATOLOGICAL TREATMENT (2021)

Add to Collection

Article Immunology

Renal Function and Patient-Reported Outcomes in Stable Kidney Transplant Patients Following Conversion From Twice-Daily Immediate-Release Tacrolimus to Once-Daily Prolonged-Release Tacrolimus: A 12-Month Observational Study in Routine Clinical Practice in Germany (ADAGIO)

Christian Hugo et al.

Summary: The study showed that converting stable kidney transplant recipients from immediate-release tacrolimus to prolonged-release tacrolimus provided stable kidney function and improved graft function over 12 months. Most patients were satisfied with prolonged-release tacrolimus, while gastrointestinal health-related quality of life was low but adherence was high.

TRANSPLANTATION PROCEEDINGS (2021)

Add to Collection

Article Dermatology

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Tiago Torres et al.

Summary: In this study, drug survival analysis of the most recent biologic agents approved for the treatment of psoriasis was conducted. Factors such as female sex, higher BMI, and prior exposure to biologic agents were found to significantly increase the risk of drug discontinuation. The study also showed that the drug survival of guselkumab and risankizumab was higher than that of ustekinumab, while secukinumab had a lower drug survival rate.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study

Marcus Schmitt-Egenolf et al.

Summary: This retrospective observational study conducted in Sweden from 2010 to 2018 analyzed 2292 adults with psoriasis who were treated with biologics. The study revealed that despite the chronic nature of psoriasis, the persistence with biologics was relatively low. Changes in therapeutic landscape influenced the persistence over time, providing patients with more options to switch biologic treatments.

DERMATOLOGY AND THERAPY (2021)

Add to Collection

Review Medicine, General & Internal

Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

Ahmed I. Mourad et al.

Summary: Drug survival studies in psoriasis assessed the comparative effectiveness of biologics like ustekinumab, adalimumab, etanercept, infliximab, secukinumab, and ixekizumab in real-world settings. Results showed ustekinumab had the longest persistence, with adalimumab outperforming etanercept and infliximab at 5 years. The estimated pooled 2- and 5-year drug survival rates can serve as a useful tool for patient communication and clinical decision-making.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Psoriatic arthritis

Oliver FitzGerald et al.

Summary: Psoriatic arthritis (PsA) is a complex inflammatory disease related to psoriasis, presenting challenges in diagnosis and treatment. There are no diagnostic criteria or tests available, and disease heterogeneity may be explained by differences in genotype. New targeted therapies have shown promise in improving outcomes for PsA patients.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Review Medicine, General & Internal

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review

April W. Armstrong et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Review Dermatology

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies

Farzad Alinaghi et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Dermatology

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Alan Menter et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Dermatology

Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis

P. de la Cueva Dobao et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)

Add to Collection

Review Clinical Neurology

An update on NMDA antagonists in depression

Bartlomiej Pochwat et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Treatment Approaches to Moderate to Severe Psoriasis

Paolo Gisondi et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

Add to Collection

Review Rheumatology

Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

Ya-Chu Tsai et al.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2017)

Add to Collection

Article Multidisciplinary Sciences

Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi

Trisha Arnold et al.

PLOS ONE (2017)

Add to Collection

Letter Dermatology

Comment on Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis

J. M. P. A. van den Reek et al.

ACTAS DERMO-SIFILIOGRAFICAS (2017)

Add to Collection

Article Dermatology

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Richard B. Warren et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis

Mingliang Zhang et al.

PATIENT PREFERENCE AND ADHERENCE (2015)

Add to Collection

Article Endocrinology & Metabolism

Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study

A. Sakai et al.

OSTEOPOROSIS INTERNATIONAL (2014)

Add to Collection

Article Dermatology

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis

Howa Yeung et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)

Add to Collection

Article Dermatology

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alan Menter et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)

Add to Collection

Article Dermatology

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis

Alan Menter et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)

Add to Collection

Article Endocrinology & Metabolism

Adherence, patient preference and dosing frequency: Understanding the relationship

JY Reginster et al.

BONE (2006)

Add to Collection

Article Dermatology

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

AB Gottlieb et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.